BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.85% | -22.02% | -19.09% | -21.92% | 3.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.76% | -13.86% | 13.68% | 43.22% | 69.55% |
| Operating Income | 30.76% | 13.86% | -13.68% | -43.22% | -69.55% |
| Income Before Tax | -221.90% | 7.61% | -26.31% | 75.71% | 66.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -221.90% | 7.61% | -26.31% | 75.71% | 66.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 95.36% | 60.49% | 191.57% | -- | -- |
| Net Income | -224.13% | 8.05% | -25.77% | 76.40% | 67.30% |
| EBIT | 30.76% | 13.86% | -13.68% | -43.22% | -69.55% |
| EBITDA | 31.16% | 14.23% | -13.34% | -42.95% | -69.60% |
| EPS Basic | -46.50% | 58.21% | -3.22% | 77.63% | 68.20% |
| Normalized Basic EPS | -47.12% | 58.47% | -2.93% | 78.02% | 68.53% |
| EPS Diluted | 55.52% | 79.77% | 48.83% | 11.27% | -4.68% |
| Normalized Diluted EPS | -41.17% | 59.27% | -1.08% | 76.82% | 67.21% |
| Average Basic Shares Outstanding | 120.84% | 59.28% | 21.51% | 5.35% | 2.89% |
| Average Diluted Shares Outstanding | 118.46% | 57.56% | 20.18% | 6.46% | 4.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |